|Patrick Flaherty, Associate Professor of Medicinal Chemistry; Ph.D. Synthetic medicinal chemistry and rational drug design, emphasis on emerging biochemical targets relevant to human disease states, modern synthetic methodology, and iterative rounds of computation, synthesis, then biochemical analysis; general therapeutic areas of interest are CNS agents and anti-cancer agents; current biological target are CDK5, microtubules, DXR, and alpha-synuclein.|
|Aleem Gangjee, Professor of Medicinal Chemistry; Mylan School of Pharmacy Distinguished Professor, Ph.D. Synthetic medicinal chemistry, computer-assisted drug design, inhibitors of folate metabolizing enzymes, receptor tyronsine kinase inhibitors, antimitotic agents, antitumor agents, antiopportunistic infection agents, nucleosides, heterocyclic chemistry and stereochemistry.|
|Marc W. Harrold, Professor of Medicinal Chemistry; Ph.D. Development of computer-based educational tools, instructional strategies in medicinal chemistry, drug design.|
|David J Lapinsky, Associate Professor of Medicinal Chemistry; Ph.D. Primarily focused on the design and synthesis of molecular probes as tools for mapping drug-binding pockets within plasma membrane monoamine (dopamine, norepinephrine, and serotonin) transporter (MAT) proteins.|
Kevin J. Tidgewell, Assistant Professor of Medicinal Chemistry; Ph.D. The Tidgewell labs primary focus is on pain and addiction with the broader scope being GPCRs involved in regulating CNS processes and other complex disease states.